A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
The purpose of this study is to determine if Eltrombopag is as effective of a treatment for patients with newly diagnosed Immune Thrombocytopenia (ITP) when compared to standard treatment.
Participants will not be paid for their participation.
- IRB Number: 1905858882 (PHO-BAYLOR-ICON3)
- Research Study Identifier: TX10529
- Principal Investigator: Kerry Hege, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required